E Fund Management Co. Ltd. Has $209,000 Stock Position in Align Technology, Inc. (NASDAQ:ALGN)

E Fund Management Co. Ltd. cut its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 30.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 764 shares of the medical equipment provider’s stock after selling 336 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Align Technology were worth $209,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ALGN. Huntington National Bank increased its position in shares of Align Technology by 94.9% during the 3rd quarter. Huntington National Bank now owns 115 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 56 shares during the last quarter. Orion Capital Management LLC bought a new stake in Align Technology during the third quarter worth $61,000. Operose Advisors LLC bought a new position in shares of Align Technology in the 3rd quarter valued at about $63,000. Covestor Ltd increased its stake in shares of Align Technology by 379.5% during the 3rd quarter. Covestor Ltd now owns 211 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 167 shares during the last quarter. Finally, Valley National Advisers Inc. increased its stake in shares of Align Technology by 29.7% during the 3rd quarter. Valley National Advisers Inc. now owns 214 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 49 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Align Technology Trading Up 0.2 %

NASDAQ ALGN opened at $281.00 on Friday. The company has a market cap of $21.15 billion, a price-to-earnings ratio of 46.19, a PEG ratio of 5.29 and a beta of 1.66. Align Technology, Inc. has a 1-year low of $176.34 and a 1-year high of $413.20. The company has a 50 day moving average of $309.52 and a 200-day moving average of $271.71.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALGN. Piper Sandler reiterated an “overweight” rating and set a $375.00 target price (up from $355.00) on shares of Align Technology in a research note on Thursday, April 25th. UBS Group upped their price objective on shares of Align Technology from $280.00 to $320.00 and gave the company a “neutral” rating in a report on Monday, April 15th. The Goldman Sachs Group raised their target price on shares of Align Technology from $197.00 to $225.00 and gave the stock a “sell” rating in a research note on Friday, February 2nd. Stifel Nicolaus upped their price target on shares of Align Technology from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Finally, Morgan Stanley increased their price target on shares of Align Technology from $344.00 to $360.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Align Technology has a consensus rating of “Moderate Buy” and a consensus target price of $353.00.

Insiders Place Their Bets

In other news, Director Joseph Lacob sold 15,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $303.22, for a total transaction of $4,548,300.00. Following the sale, the director now directly owns 131,994 shares of the company’s stock, valued at approximately $40,023,220.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.62% of the company’s stock.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.